Our goal is to become a leading biopharmaceutical company focused primarily on products for the treatment of CNS disorders. The key elements of our strategy are to:

• Pursue development and commercialization of our lead product candidates
• Expand our product candidate portfolio with novel drug candidates that address unmet needs in large, established markets 
• Reduce clinical development and commercialization risk by building a diversified product portfolio
• Selectively establish collaborations with global pharmaceutical companies to assist in the development of our products, mitigate financial risk and retain significant commercial upside